[{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Eniluracil","moa":"||Dihydropyrimidine dehydrogenase","graph1":"Oncology","graph2":"Phase II","graph3":"Processa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Processa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Processa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Eniluracil","moa":"||Dihydropyrimidine dehydrogenase","graph1":"Oncology","graph2":"Phase II","graph3":"Processa Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Processa Pharmaceuticals \/ Alliance Global Partners","highestDevelopmentStatusID":"8","companyTruncated":"Processa Pharmaceuticals \/ Alliance Global Partners"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Eniluracil","moa":"||Dihydropyrimidine dehydrogenase","graph1":"Oncology","graph2":"Phase II","graph3":"Processa Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Processa Pharmaceuticals \/ Alliance Global Partners","highestDevelopmentStatusID":"8","companyTruncated":"Processa Pharmaceuticals \/ Alliance Global Partners"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Eniluracil","moa":"||Dihydropyrimidine dehydrogenase","graph1":"Oncology","graph2":"Phase II","graph3":"Processa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Processa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Processa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Eniluracil","moa":"||Dihydropyrimidine dehydrogenase","graph1":"Oncology","graph2":"Phase I","graph3":"Processa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Processa Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"Processa Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Aposense","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Irinotecan Hydrochloride","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Undisclosed","graph3":"Processa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Processa Pharmaceuticals \/ Aposense","highestDevelopmentStatusID":"1","companyTruncated":"Processa Pharmaceuticals \/ Aposense"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Eniluracil","moa":"||Dihydropyrimidine dehydrogenase","graph1":"Oncology","graph2":"Phase I","graph3":"Processa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Processa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Processa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Eniluracil","moa":"||Dihydropyrimidine dehydrogenase","graph1":"Oncology","graph2":"Phase I","graph3":"Processa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Processa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Processa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"PCS499","moa":"cGMP\/PDE","graph1":"Dermatology","graph2":"Phase II","graph3":"Processa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Processa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Processa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Capecitabine","moa":"||DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Processa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Processa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Processa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Preclinical","graph3":"Processa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Processa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Processa Pharmaceuticals \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Processa Pharmaceuticals

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          AACR Annual meeting
                          Not Confirmed
                          AACR Annual meeting
                          Not Confirmed

                          Details : The net proceeds will used to fund the clinical development of PCS6422 (eniluracil), which is being evaluated for the treatment of breast neoplasms.

                          Product Name : PCS6422

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          January 30, 2025

                          Lead Product(s) : Eniluracil,Capecitabine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Alliance Global Partners

                          Deal Size : $5.0 million

                          Deal Type : Public Offering

                          blank

                          02

                          AACR Annual meeting
                          Not Confirmed
                          AACR Annual meeting
                          Not Confirmed

                          Details : The net proceeds will used to fund the clinical development of PCS6422 (eniluracil), which is being evaluated for the treatment of breast neoplasms.

                          Product Name : PCS6422

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          January 27, 2025

                          Lead Product(s) : Eniluracil,Capecitabine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Alliance Global Partners

                          Deal Size : $5.0 million

                          Deal Type : Public Offering

                          blank

                          03

                          AACR Annual meeting
                          Not Confirmed
                          AACR Annual meeting
                          Not Confirmed

                          Details : NGC-Cap is PCS6422 (eniluracil) administered in combination with capecitabine, a precursor of the cancer drug 5-FU. It is being evaluated for the treatment of gastrointestinal cancer.

                          Product Name : PCS6422

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 06, 2024

                          Lead Product(s) : Eniluracil,Capecitabine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          AACR Annual meeting
                          Not Confirmed
                          AACR Annual meeting
                          Not Confirmed

                          Details : NGC-Iri is a prodrug of SN-38, the active molecule in irinotecan and Onivyde. It is currently being evaluated for the treatment of cancers.

                          Product Name : NGC-Iri

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 19, 2024

                          Lead Product(s) : Irinotecan Hydrochloride

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          AACR Annual meeting
                          Not Confirmed
                          AACR Annual meeting
                          Not Confirmed

                          Details : PCS6422 is an analog of uracil that irreversibly inhibits dihydropyrimidine dehydrogenase (DPD) enzyme, being developed for the treatment of breast cancer.

                          Product Name : PCS6422

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 30, 2024

                          Lead Product(s) : Eniluracil,Capecitabine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          AACR Annual meeting
                          Not Confirmed
                          AACR Annual meeting
                          Not Confirmed

                          Details : PCS6422 is an analog of uracil that irreversibly inhibits dihydropyrimidine dehydrogenase (DPD) enzyme, being developed for the treatment of breast cancer.

                          Product Name : PCS6422

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 10, 2024

                          Lead Product(s) : Eniluracil,Capecitabine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          AACR Annual meeting
                          Not Confirmed
                          AACR Annual meeting
                          Not Confirmed

                          Details : NGC-Cap is PCS6422 (eniluracil) administered in combination with capecitabine, a precursor of the cancer drug 5-FU. It is being evaluated in phase 1 clinical trials for gastrointestinal cancer.

                          Product Name : PCS6422

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 25, 2024

                          Lead Product(s) : Eniluracil,Capecitabine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          AACR Annual meeting
                          Not Confirmed
                          AACR Annual meeting
                          Not Confirmed

                          Details : The net proceeds will be used to advance the development of PCS6422 (eniluracil) administered in combination with capecitabine, for the treatment of advanced, refractory gastrointestinal tract tumors.

                          Product Name : PCS6422

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          January 02, 2024

                          Lead Product(s) : Eniluracil,Capecitabine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : H.C. Wainwright & Co

                          Deal Size : $7.0 million

                          Deal Type : Public Offering

                          blank

                          09

                          AACR Annual meeting
                          Not Confirmed
                          AACR Annual meeting
                          Not Confirmed

                          Details : NGC-Cap combines the administration of PCS6422, the Company’s irreversible dihydropyrimidine dehydrogenase (DPD) enzyme inhibitor, with the administration of low doses of the commonly used chemotherapy capecitabine.

                          Product Name : NGC-Cap

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 19, 2023

                          Lead Product(s) : Capecitabine,Eniluracil

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          AACR Annual meeting
                          Not Confirmed
                          AACR Annual meeting
                          Not Confirmed

                          Details : With input from the FDA, Processa will be designing and conducting a Phase 3 trial to evaluate the ability of PCS499 to completely close ulcers in patients with NL.

                          Product Name : PCS499

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 30, 2020

                          Lead Product(s) : PCS499

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank